Biogen Inc. (BIIB)

From the record

Biogen Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Biogen Inc.'s 10 filed years say what it did: revenue went from $11 billion in fiscal 2016 to $9.9 billion in fiscal 2025, down 1.6% a year; it rose in 4 of 9 years; the deepest fall was 33% from fiscal 2019 to fiscal 2024; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Biogen Inc.'s diluted share count grew about 0.3% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 4 sales (4 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-11-02, buying about $1 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Biogen Inc. earned about 7 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 25 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 38 cents per dollar of assets, and net share issuance: its share count grew 0.8% over the year (the filed statements).

From the record

Biogen Inc.'s standing among 102 graded names in its industry family: revenue of $9.9 billion in fiscal 2025 ranks in the top 2% by size; a net margin of 13.1% ranks in the top 17%; revenue growth of -0.9% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).

From the record

Biogen Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Viehbacher, Christopher (President and CEO, as filed), filing under that title since 2022-11-21, 4 years (bottom 41% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 4.4 years (bottom 27%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (top 19%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Biogen Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3.0 billion against debt of $6.3 billion leaves -11.1% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 20.7% of revenue (top 12%); a gross margin of 75.7% (top 41%); research spending of 18% of revenue (bottom 13%) (its annual report).

From the record

Biogen Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.9% a year over the last three filed years against -1.6% over all 10, speeding up (top 27% of its family); the newest year grew 2.2% (bottom 37%); research spending grew -7.3% a year (bottom 32%); capital spending grew -13.8% a year (top 35%) (its annual reports). Biogen Inc. reported 12 product lines in fiscal 2025: SPINRAZA at $1.5 billion (16%), Fumarate at $1.4 billion (14%), Royalty Attributed to OCREVUS at $1.4 billion (14%), and 9 more; 5 of 12 grew against the year before (its annual report).

From the record

Biogen Inc.'s newest year against its own record: revenue of $9.9 billion in fiscal 2025 came in 4.8% above the $9.4 billion its prior three years' pace pointed to (top 47% of its family); net income of $1.3 billion against a prior three-year average of $1.9 billion (bottom 25%); a net margin of 13.1% against 19.5% before (bottom 31%) (its annual reports).